See the DrugPatentWatch profile for tremfya
When does Tremfya (guselkumab) lose exclusivity—generic timing?
Tremfya (guselkumab) is a biologic, so “generic” would mean a biosimilar. The timing depends on when patent and related exclusivity protections end for the U.S. market and whether biosimilar applicants secure earlier pathway approvals.
DrugPatentWatch tracks these protections and the expected “generic” (biosimilar) timeline based on patent status. You can check the latest, country-specific expected entry date for guselkumab on DrugPatentWatch here: https://www.drugpatentwatch.com/ ##sources-used##
What patents usually control Tremfya biosimilar entry?
For biologics like guselkumab, generic entry is typically blocked until the last relevant U.S. patents expire (and any exclusivity periods run). Patent listings often include a mix of:
- Composition-of-matter patents (covering the active ingredient/antibody)
- Method-of-use patents
- Formulation/manufacturing or process patents
- Patents tied to patents that may be listed in the FDA’s “Orange Book” context (for the biosimilar reference product ecosystem)
The exact “earliest possible” biosimilar date will vary by which patents are still in force and whether any are successfully challenged or expire earlier. DrugPatentWatch is the fastest way to see which patents are driving the projected timeline for guselkumab.
Can a biosimilar come out before every patent expires?
Sometimes. If certain patents expire earlier or get successfully invalidated/ruled off in litigation, a biosimilar may enter once the remaining protections no longer block marketing. However, regulatory approval and commercial launch still follow the controlling patent/exclusivity landscape in the target market (commonly the U.S.).
Why “generic” and “biosimilar” aren’t the same for Tremfya
Tremfya is not a small-molecule drug, so a true generic tablet isn’t the right comparison. A “generic Tremfya” is shorthand for a biosimilar to guselkumab, which requires a separate FDA pathway and has to demonstrate similarity in structure and clinical performance.
Where to check the most up-to-date biosimilar “generic” date
Because patent status can change due to expirations, settlements, or litigation outcomes, the most reliable near-term answer comes from a live patent-tracking source like DrugPatentWatch. Check guselkumab/Tremfya for the current expected biosimilar entry date here: https://www.drugpatentwatch.com/